Passage Bio (PASG) Competitors $7.20 +0.07 (+0.91%) Closing price 03:59 PM EasternExtended Trading$6.80 -0.40 (-5.49%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. VIRI, IMUX, ABOS, EPIX, CELU, OKYO, PLRX, LIMN, ELUT, and ENTXShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Virios Therapeutics (VIRI), Immunic (IMUX), Acumen Pharmaceuticals (ABOS), ESSA Pharma (EPIX), Celularity (CELU), OKYO Pharma (OKYO), Pliant Therapeutics (PLRX), Liminatus Pharma (LIMN), Elutia (ELUT), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors Virios Therapeutics Immunic Acumen Pharmaceuticals ESSA Pharma Celularity OKYO Pharma Pliant Therapeutics Liminatus Pharma Elutia Entera Bio Passage Bio (NASDAQ:PASG) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Is PASG or VIRI more profitable? Passage Bio's return on equity of -103.87% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Passage BioN/A -103.87% -59.95% Virios Therapeutics N/A -130.33%-115.00% Does the media refer more to PASG or VIRI? In the previous week, Virios Therapeutics had 1 more articles in the media than Passage Bio. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.50 beat Virios Therapeutics' score of 0.00 indicating that Passage Bio is being referred to more favorably in the media. Company Overall Sentiment Passage Bio Positive Virios Therapeutics Neutral Which has higher earnings & valuation, PASG or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPassage BioN/AN/A-$64.77M-$18.16-0.40Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.24 Do insiders & institutionals have more ownership in PASG or VIRI? 53.5% of Passage Bio shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 5.0% of Passage Bio shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend PASG or VIRI? Passage Bio presently has a consensus price target of $75.67, suggesting a potential upside of 951.66%. Virios Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 1.52%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, PASG or VIRI? Passage Bio has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. SummaryPassage Bio beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.65M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-0.407.5859.1122.53Price / SalesN/A458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book0.369.9310.916.06Net Income-$64.77M-$53.38M$3.29B$266.28M7 Day Performance2.93%0.05%0.01%-0.76%1 Month Performance25.35%7.08%7.06%3.83%1 Year Performance-47.73%11.92%50.09%24.39% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio3.0904 of 5 stars$7.20+0.9%$75.67+951.7%-46.1%$22.65MN/A-0.40130VIRIVirios Therapeutics0.1275 of 5 stars$4.95+0.2%$5.00+1.0%+2,528.5%$95.30MN/A-18.335IMUXImmunic2.7611 of 5 stars$0.88-7.7%$7.50+755.4%-42.5%$93.72MN/A-0.7170Analyst RevisionABOSAcumen Pharmaceuticals2.8528 of 5 stars$1.51-1.3%$7.00+363.6%-43.3%$92.68MN/A-0.6620EPIXESSA Pharma3.2672 of 5 stars$0.78-59.4%$2.00+155.1%-96.0%$91.31MN/A-1.4050Dividend AnnouncementGap DownHigh Trading VolumeCELUCelularity0.7282 of 5 stars$3.84+1.3%$6.00+56.3%-10.5%$90.77M$54.22M-1.45220Earnings ReportOKYOOKYO Pharma3.2374 of 5 stars$2.43+2.5%$7.00+188.1%+97.4%$89.14MN/A0.007News CoverageShort Interest ↓PLRXPliant Therapeutics4.089 of 5 stars$1.49+2.8%$8.19+449.5%-86.6%$89.01M$1.58M-0.4490News CoveragePositive NewsLIMNLiminatus PharmaN/A$3.40-0.3%N/AN/A$88.71MN/A0.00N/AELUTElutia3.3089 of 5 stars$2.39+14.4%$8.00+234.7%-51.0%$88.61M$24.38M-2.25180News CoverageGap UpHigh Trading VolumeENTXEntera Bio1.3778 of 5 stars$1.95+0.5%$10.00+412.8%+0.5%$88.59M$180K-7.5020Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies VIRI Alternatives IMUX Alternatives ABOS Alternatives EPIX Alternatives CELU Alternatives OKYO Alternatives PLRX Alternatives LIMN Alternatives ELUT Alternatives ENTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PASG Stock Alerts